China Pharma Holdings acquires topiroxostat nanoemulsion patent for $8.82M in stock

CHINA PHARMA HOLDINGS, INC.

Transfer price of $8.82M paid in 12.6M restricted shares at $0.70/share; closing by Feb 20, 2026.
Transferor Xiaoyun Chen to provide technical services including R&D and registration.
Transferor also entitled to 3% of net profit from product after commercial launch.
Patent covers Topiroxostat Nanoemulsion and method; patent expires July 2036.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Xiaoyun Chen valued at $8.82 million in common stock at $0.70 per share (effective 2026-02-05).

Action: entry
Agreement: license
Counterparty: Xiaoyun Chen
Value: $8.82 million in common stock at $0.70 per share
Effective: 2026-02-05

Exact text from the filing

On February 5, 2026 (the "Signing Date"), Hainan Helpson Medical & Biotechnology Co., Ltd (" Helpson "), a wholly owned subsidiary of China Pharma Holdings, Inc. (the " Company "), entered into a Technology Transfer Agreement (the " Agreement ") with Xiaoyun Chen (the " Transferor ").

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

CHINA PHARMA HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-014338

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.